Dissemin is shutting down on January 1st, 2025

Published in

Nature Research, Nature Chemical Biology, 3(11), p. 189-191, 2015

DOI: 10.1038/nchembio.1735

Links

Tools

Export citation

Search in Google Scholar

Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation

Journal article published in 2015 by John Liddle, Huw D. Lewis, Jim E. Coote, Stephen J. Atkinson, Michael D. Barker, Benjamin D. Bax, Kevin L. Bicker, Ryan P. Bingham, Matthew Campbell, Yu Hua Chen, Chun-Wa Chung, Peter D. Craggs ORCID, Rob P. Davis, Dirk Eberhard, Gerard Joberty and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

PAD4 has been strongly implicated in the pathogenesis of autoimmune, cardiovascular and oncological diseases through clinical genetics and gene disruption in mice. New selective PAD4 inhibitors binding a calcium-deficient form of the PAD4 enzyme have validated the critical enzymatic role of human and mouse PAD4 in both histone citrullination and neutrophil extracellular trap formation for, to our knowledge, the first time. The therapeutic potential of PAD4 inhibitors can now be explored.